Table 2.

Univariate analysis and multivariate analysis of the correlation of the GNPNAT1 expression with overall survival among lung adenocarcinoma patients in TCGA-LUAD cohort.

Variable	Univariate Cox analysis				Multivariate Cox analysis∗
	Coef	HR (95% CI)	z	p value	Coef	HR (95% CI)	z	p value
Age	0.00865	1.01 (0.993-1.02)	1.12	0.264
Gender (male vs. female)	0.0584	1.06 (0.792-1.42)	0.393	0.694
Stage II (vs. stage I)	0.904	2.47 (1.72-3.55)	4.87	1.13E-06	1.06	2.88 (1.11-7.48)	2.17	0.03
Stage III (vs. stage I)	1.27	3.57 (2.44-5.22)	6.55	5.72E-11	0.5	1.65 (0.442-6.14)	0.745	0.456
Stage IV (vs. stage I)	1.34	3.81 (2.2-6.62)	4.76	1.95E-06	-0.167	0.846 (0.24-2.99)	-0.259	0.796
Race (white vs. nonwhite)	0.359	1.43 (0.875-2.34)	1.43	0.154
Ethnicity (Hispanic and Latino vs. non-Hispanic and Latino)	0.384	1.47 (0.464-4.64)	0.654	0.513
Tobacco smoking history (ever vs. never)	-0.12	0.887 (0.587-1.34)	-0.571	0.568
Number pack years smoked	0.00327	1 (0.996-1.01)	0.936	0.349
Radiation therapy (yes vs. no)	0.762	2.14 (1.44-3.19)	3.75	0.000175	0.289	1.34 (0.368-4.84)	0.439	0.66
Additional radiation therapy (yes vs. no)	-0.0197	0.981 (0.622-1.55)	-0.0847	0.932
Additional pharmaceutical therapy (yes vs. no)	-0.5	0.607 (0.383-0.962)	-2.13	0.0334	-0.814	0.443 (0.21-0.933)	-2.14	0.0322
KRAS mutation (yes vs. no)	0.492	1.63 (0.672-3.98)	1.08	0.278
EGFR mutation (yes vs. no)	0.268	1.31 (0.828-2.06)	1.15	0.25
EML4-ALK translocation (yes vs. no)	0.592	1.81 (1.01-3.24)	1.98	0.0473	0.771	2.16 (0.833-5.61)	1.58	0.113
Location in lung parenchyma (central lung vs. peripheral lung)	0.0908	1.09 (0.684-1.75)	0.378	0.706
Tumor intermediate dimension	0.411	1.51 (0.895-2.54)	1.54	0.122
GNPNAT1	0.519	1.68 (1.38-2.05)	5.09	3.60E-07	1.03	2.81 (1.48-5.36)	3.15	0.00166

^∗Concordance = 0.746 (se = 0.042), likelihood ratio test = 24.58 on 7 df, p = 9e − 04, Wald test = 22.07 on 7 df, p = 0.002, score (logrank) test = 24.16 on 7 df, p = 0.001.